Search | Clinical Trials Finder

Conditions: Migraine
Interventions: TEZAMPANEL; Drug
Lead sponsor: TorreyPines Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
Interventions: Durvalumab, Lurbinectedin; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Fall, Fear of Falling, Physical Inactivity, Sedentary Behavior
Interventions: Physio-feedback, Cognitive reframing, Peer-led exercises, CDC older adults fall prevention; Behavioral
Lead sponsor: University of Central Florida; Other
Eligibility: 60 Years and older
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Stanford, California • Torrance, California • Iowa City, Iowa + 7 more

Conditions: Sedentary Lifestyle, Cigarette Smoking
Interventions: PA+ Smoking Cessation (LMPA), Standard Care Smoking Counseling (SCC); Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: LCA5
Interventions: AAV8.hLCA5; Biological
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 4 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Rabies, Rabies Immunisation
Interventions: ChAd155-RG, Placebo, Rabies Vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions: RBS2418, Placebo; Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Newark, Delaware • Kingwood, Texas

Conditions: Actinic Keratosis
Interventions: LEO 43204 Gel, 0.037%; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Quincy, Massachusetts • Smithtown, New York

Conditions: Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions: nfant feeding solution; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 6 Months
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome
Interventions: Restorative yoga therapy; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anesthesia
Interventions: Thoracic epidural block, Electrical Nerve stimulation, Solution For Thoracic epidural block; Procedure · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Obsessive-Compulsive Disorder
Interventions: Gradual Exposure (EXP-G), Variable Exposure (EXP-V); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 20
States / cities: Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more

Conditions: Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
Interventions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions; Biological
Lead sponsor: Guenther Koehne; Other
Eligibility: 18 Years to 74 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dysphagia, GERD, Degenerative Joint Disease
Interventions: Esomeprazole, Placebo Oral Tablet; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Muscular Atrophy, Spinal
Interventions: Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Palo Alto, California • New York, New York

Conditions: Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 5,377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2021
U.S. locations: 210
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more

Conditions: Postpartum, Neuromuscular Adaptations, Abdominal Muscles, Pelvic Floor Dysfunctions, Physical Activity
Interventions: Progressive exercise, Active Straight Leg Raise Test, Active Straight Leg Raise Fatigue Task, Lower Extremity Strength Testing, Ultrasound imaging of abdominal wall, Pelvic Floor Muscle Strength Testing, Pelvic Floor Muscle Endurance Testing; Other · Diagnostic Test
Lead sponsor: Carroll University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Placebo, Ianalumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 17
States / cities: Mesa, Arizona • Los Angeles, California • Newport Beach, California + 14 more

Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions: ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox, flow cytometry, immunoenzyme technique; Drug · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: B-MPH; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 4 Years to 5 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions: Axitinib, Nivolumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 266
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 168 more

Conditions: Diet Modification, Lung Cancer
Interventions: Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control); Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Optimizing a Technology-based Body and Mind Intervention

Comparison of Delivery Routes of Flu Vaccine in Adults

Step-up to Quit: Using Low-to-moderate Intensity Exercise for Reducing Smoking Cue Reactivity Among Low-income Smokers

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Biological Effects of LEO 43204 in Actinic Keratosis

Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

Yoga for the Treatment of Metabolic Syndrome

Loss of Resistance, w/wo Stimulation, For Epidural Placement

Methods for Managing Intrusive Thoughts

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Postpartum Exercise Intervention

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Long-Duration Stimulant Treatment Study of ADHD in Young Children

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Reducing Insulin, Growth Hormones, and Tumors